Advanced Practice Providers Oncology Summit

ONLINE ON DEMAND CE COURSES IN ONCOLOGY

Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers - 2025

The demand for cancer care is expected to increase by 40% over the next six years; however, ASCO is projecting a shortage of more than 2,200 oncologists by 2025. To meet the cancer care needs of all patients, advanced practice providers (APPs), whose education and training focus on health promotion, disease prevention, and primary care medical management, have been increasingly sought-after to fill this shortage. However, many new APPs have little background and training in oncology. As a result, oncology practices need to provide new staff with an onboarding program to help further their knowledge of hematology and oncology. To assist APPs in their new careers in oncology-based practices, Horizon CME, in partnership with APAO, has developed “Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers.” In this two-and-a-half-day virtual program, clinicians will gain a greater understanding of cancer treatment, cancer therapies, side effects, supportive care strategies, palliative care, and more. Expert faculty will provide a detailed review of treatment strategies for hematologic disorders and solid malignancies. Participation in the program will allow APPs to build upon the foundational knowledge acquired in Oncology 101 and provide APPs with a deeper understanding of the cancer treatment strategies they need to support and care for cancer patients as part of the multidisciplinary oncology care team.

(Course access available through December 4, 2025)

Cost

$150

GO HERE TO TAKE THE COURSE

Target Audience

This activity is intended for oncology nurse practitioners, physician assistants, nurses, nurse navigators, medical assistants, and other healthcare providers involved in the care of cancer patients.

Faculty

PLANNING COMMITTEE

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN

Nurse Practitioner Department of Hematology and Medical Oncology - Cleveland Clinic 

Beth Sandy, MSN, CRNP

Nurse Practitioner, Thoracic Medical Oncology Abramson Cancer Center, University of Pennsylvania

Val R. Adams, PharmD, FCCP, FHOPA, BCOP

Associate Professor, Oncology Specialist - University of Kentucky

Leigh Ann Childress MSN, NP, AOCNP

Director of Advanced Practice Clearview Cancer Institute Huntsville, AL

Danielle Roberts PA-C

Physician assistant with the Bone Marrow Transplant team Winship Cancer Institute of Emory University Atlanta, GA

PRESENTING FACULTY

Jennie M. Goble, PA-C

Instructor in Medicine - Mayo Clinic Rochester, MN

Sandra Cuellar Puri, PharmD, BCOP

Clinical Oncology Pharmacist University of Illinois College of Pharmacy Chicago, IL

Anthony J Olszanski, RPh, MD

Physician Fox Chase Cancer Center Philadelphia, PA

Greata Russler, MSN, FNP-BC

Nurse Practitioner Winship Cancer Institute of Emory University Atlanta, GA

Kathryn Green, CRNP, MSN

Nurse Practitioner Abramson Cancer Center, University of Pennsylvania Philadelphia, PA

Rachel Frankenthal, PA-C

Physician Assistant UCLA Health Los Angeles, CA

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Nurse Practitioner Yale-New Haven Yale Comprehensive Cancer Center New Haven, CT

Taylor Aldridge

Physician Assistant Standford Healthcare Standford, CA

Vanessa Nevins, PA-C, RDMS, RT

Physician Assistant Yale New Haven Smilow Cancer Hospital New Haven, CT

Krisin Daily, MSN, ANP-BC AOCNP

Nurse Practitioner St. Louis School of Medicine St. Louis, MO

Laura Wood, RN, MSN, OCN

Nurse Cleveland Clinic, Taussig Cancer Center Cleveland, OH

Kayla Freeman, DNP, APRN, FNP-C

Nurse Practitioner Emory Winship Cancer Institute Atlanta, GA

Lauren Imboden

Physician Assistant Atrium Health Wake Forest Baptist Winston-Salem, NC

Amitkumar Mehta, MD

Physician University of Alabama Tuscaloosa, Alabama

Lisa Nodzon PhD, APRN, AOCNP

Nurse Practitioner H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

Ann Katz, PhD, RN, FAAN, AASECT-Certified Sexuality Counselor

Nurse CancerCare Manitoba Winnipeg, Canada

Alicia M. Rigby MSN, RN, APRN, AOCNP

Nurse Practitioner UC Davis Cancer Center Sacramento, CA

Tanya Uritsky PharmD, BCPP

Opioid Stewardship Coordinator University of Pennsylvania (HUP) Philadelphia, PA

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner Icahn School of Medicine at Mount Sinai Hospital New York, NY

Suzanne McGettigan CRNP

Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing Perelman Center for Advanced Medicine, Abramson Cancer Center Philadelphia, PA

Bridget Harr CNP

Nurse Practitioner Cleveland Clinic Cleveland, OH

Amy Goodrich, RN, MSN, CRNP

Nurse Practitioner Johns Hopkins Baltimore, MD

Peter Hakos, PA-C

Physician Assistant Cleveland Clinic Cleveland, OH

Sujata Kane, MS, RD, PA-C

Nurse Practitioner Winship Cancer Institute, Emory University Atlanta, GA

DISCLOSURES

 

DISCLOSURES:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Planners

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Faculty, Authors, and Content Developers Disclosures

  • Anthony J. Olszanski, RPh, MD discloses advisory board with BMS, Merck, Pfizer, Novartis, Eisai, Nectar, InstillBio but these relationships have ended and contracted research with Alkermes, antegene, Elucida, Eutilex, GSK, HiFiBio, Immatics during the past 24 months.
  • Suzanne McGettigan, CRNP discloses speaker’s bureau with BMS, Regeneron, Merck, Pfizer during the past 24 months.
  • Beth Sandy, MSN, CRNP discloses speaker’s bureau with Merck Takeda, AstraZeneca, Jazz Amgen and advisory boards with Abbvie and Janssen during the past 24 months.  
  • Greta Russler, MSN, FNP-BC discloses advisory boards with BMS during the past 24 months.
  • Laura S. Wood, RN, MSN, OCN discloses speaker’s bureau with AVEO, BMS, Exelixis, EMD, Serono, Merck, Pfizer during the past 24 months.  
  • Kristin M. Daly, MSN, ANP-BC, AOCNP discloses advisory boards with Eisai but this relationship has ended during the past 24 months.
  • Kathryn L. Green, CRNP, MSN discloses speaker’s bureau with AstraZeneca and advisory boards with AadiBio during the past 24 months.
  • Rachel Frankenthal, PA-C discloses advisory boards with Immunogen and GSK but these relationships have ended during the past 24 months.
  • Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN discloses Advisory Board and Consulting Fee with Janssen, Sanofi, Karyopharm during the past 24 months.
  • Donna Catamero, ANP-BC, OCN, CCRC discloses speaker’s bureau with speaker’s bureau with Johnson & Johnson, Bristol Myers Squibb, and advisory boards with Johnson and Johnson, Legend, Sanofi, Pfizer, BMS, and consulting fees with Johnson and Johnson during the past 24 months.
  • Lisa Nodzon PhD, APRN, AOCNP discloses Speaker’s Bureau with Pharmacyclics AstraZeneca and Speaker’s Bureau with Takeda and Genentech/AbbVie but that relationship has ended.Advisory Board with BeiGene; Pharmacyclics, Novartis and Consulting Fee with AstraZeneca; AbbVie during the past 24 months.
  • Amy Goodrich, RN, MSN, CRNP discloses advisory boards with Abbvie, AstraZeneca, BieGene, Fresenuis during the past 24 months.
  • Peter Hakos, PA-C – discloses stock ownership with Pfizer and AbbVie during the past 24 months.
  • Lauren Imboden, PA-C discloses advisory boards with Sanofi and Genzyme but this relationship has ended during the past 24 months.
  • Amitkumar Mehta, MD discloses speaker’s bureau with Incyte/Morphosys, BeiGen, Ipsen, consulting fees with Gilead, Seattle Genetics, Incyte, and contracted research with Incyte, Takeda, forty-seven inc/Gilead during the past 24 months.

Planners:

  • Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN discloses consulting fees with Amgen, BMS, Janssen, Pfizer, and Karyopharm during the past 24 months.
  • Val R. Adams, PharmD, FCCP, FHOPA, BCOP discloses contracted research with BMS during the past 24 months.
  • Beth Sandy, MSN, CRNP discloses advisory boards with Amgen, BMS, Janssen, Pfizer, Karyopharm, Abbvie, and Janssen during the past 24 months.
  • Leigh Ann Childress, MSN, NP, AOCNP discloses speaker’s bureau with AstraZeneca, Seagen, Sobi, Merck, Amgen during the past 24 months.